Biotechnology

SpyBiotech, a UK-based biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.   This project will harness SpyBio’s ‘plug and display’ technology to design a broadly cross-protective […]

Aldena Therapeutics, a biotech company that is pioneering siRNA-based therapies for dermatological indications, has updated its immuno-dermatology pipeline, appointed a Scientific Advisory Board (SAB), and announced $30 million financing by Medicxi.  Pipeline  Under the leadership of Thibaud Portal, CEO of Aldena, the company’s goal is to develop advanced, long-lasting treatments for dermatological diseases based on […]

iOnctura, a clinical stage biotechnology company developing cancer therapies, has published non-clinical research on roginolisib in the AACR journal Cancer Research Communications. Roginolisib is a first-in-class, non-ATP-competitive, allosteric modulator of PI3Kd which prevents tumour proliferation and breaks immune tolerance in patients with solid and haematological tumours.    The research   PI3Kδ inhibition in solid tumours has […]

Ahead of the UK’s Spring Budget, the UK BioIndustry Association (BIA) is calling on the Treasury to provide additional support through the R&D tax relief scheme to R&D intensive SMEs. These companies are the most at risk from the R&D tax relief rate cut announced at the Autumn Statement, due to their high R&D investment […]

Teitur Trophics, a biotech company developing new treatments for patients suffering from neurodegenerative diseases, has complete a €28M Series A financing.   The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead […]

Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, has shared topline monotherapy data from the biliary tract cancer (BTC) module of the RXC004 PORCUPINE2 Phase II clinical trial programme. RXC004 is an orally active, once daily, porcupine inhibitor being […]

Gary Connors, Partner at business consulting company Oliver Wight EAME looks at some of the most important factors that will affect the pharmaceutical industry going forward.   We advise all our clients to make assumptions and think about scenarios that could affect their business at least five years in advance. I’m not a futurist, neither […]

Kristina Tatiossian, PhD, founder of Arkitekt Agency, looks at how biotech companies are currently using social media and provides a five-step guide for how to make the most of this ubiquitous marketing tool. Biotechnology organisations can leverage social media for a variety of purposes, from boosting awareness and increasing engagement, to connecting with stakeholders and […]

Ahead of this year’s SLAS2023 conference in San Diego (which takes place 25 February – 1 March), DDW’s Megan Thomas narrates articles from the DDW SLAS2023 supplement as part of the DDW Events podcast series. This is episode one, A Welcome to SLAS 2023, which includes two comment pieces. Thomas wrote the first one, We […]

San Francisco-based biotechnology company Infinimmune is emerging from stealth with its $12 million seed financing. The company is co-founded by former team leaders and multi-disciplinary tool builders from 10x Genomics. Taking a human-first approach, Infinimmune is leveraging single-cell technology to create truly human antibody-based therapeutics directly derived from the human immune system. DDW’s Megan Thomas […]